SGLT2 Inhibitors Clinical Trials SGLT2 Inhibitors RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Empagliflozin Addition in Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia Patients
Condition:   Sodium-glucose Transport Protein Two Inhibitor (SGLT2),Metabolic Deficits Caused by Antipsychotics Interventions:   Drug: Empagliflozin;   Drug: olanzapine Sponsor:   Tanta University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 3, 2023 Category: Research Source Type: clinical trials